Imunon Inc (IMNN)

$0.88 -0.01 (-0.86%)
Market Cap 16.17M
Revenue (ttm) 0.00
Net Income (ttm) -18.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 453,391
Avg Vol 13,923,456
Day's Range N/A - N/A
Shares Out 17.54M
Stochastic %K 4%
Beta 2.13
Analysts Strong Sell
Price Target $10.25

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 896 9100
Website: imunon.com
Address:
997 Lenox Drive, Suite 100, Lawrenceville, United States
NFD2
NFD2 Jun. 25 at 4:57 PM
$IMNN Imunon on #LinkedIn. Be sure to give them a follow!
0 · Reply
Yvon2025
Yvon2025 Jun. 25 at 4:35 PM
$IMNN By letting the stock price goes down that dip, the executives are sending a clear message: R/S is coming soon. Very painful they are planning to do this.
0 · Reply
RandomInvestor777
RandomInvestor777 Jun. 25 at 4:30 PM
$IMNN got some out of my fund to buy, however i will slowly buy as it goes down. This company is either getting a buyout or a partnership soon Imo. Their medicine is legit.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 Jun. 25 at 4:03 PM
$IMNN couldn’t buy today. Waiting for some money to clear. Should be good tomorrow for more shares.
0 · Reply
Cello69
Cello69 Jun. 25 at 3:40 PM
$IMNN Added .86
0 · Reply
Investnow54
Investnow54 Jun. 25 at 3:36 PM
$IMNN i would not care either if i knew i was going to be bought out. Its been explained the medicine works prolongs life where no one else can. I do not think phase 3 will just fall apart. This is robbery if your shares and lack of patience at play.
1 · Reply
ZacksSCR
ZacksSCR Jun. 25 at 3:07 PM
Replay available now: @OTCMarkets Virtual Investor Presentation with Stacy Lindborg, President, CEO, & Board Director of Imunon $IMNN, and David Bautz, PhD, SCR Senior Analyst https://buff.ly/IYhksSk #Biotech #DNAImmunotherapy #ImmunoOncology
0 · Reply
Goldpay55
Goldpay55 Jun. 25 at 2:58 PM
$IMNN at this pace we should be below .50 next week. Very disappointing to say the least
0 · Reply
I_AM_GROOT
I_AM_GROOT Jun. 25 at 2:49 PM
$IMNN shorty getting in before the 100K dump later today at the close like yesterday. They aren't dumb when it's telegraphed.
0 · Reply
OilBoomer
OilBoomer Jun. 25 at 1:49 PM
$IMNN Thought about selling this for a 30% loss but I'm just gonna hold and see if it doubles or goes to 0, not worth looking at each and every day.
0 · Reply
Latest News on IMNN
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Jun 18, 2025, 8:05 AM EDT - 7 days ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Jun 17, 2025, 8:05 AM EDT - 8 days ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Jun 3, 2025, 8:05 AM EDT - 22 days ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

Jun 2, 2025, 8:05 AM EDT - 23 days ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

May 27, 2025, 8:05 AM EDT - 4 weeks ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

May 23, 2025, 6:59 PM EDT - 4 weeks ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

May 23, 2025, 8:05 AM EDT - 4 weeks ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Withdrawal of Form S-1 Registration Statement

May 22, 2025, 5:20 PM EDT - 4 weeks ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

May 15, 2025, 8:05 AM EDT - 5 weeks ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

May 12, 2025, 12:56 PM EDT - 6 weeks ago

Imunon, Inc. (IMNN) Q1 2025 Earnings Call Transcript

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 8:00 AM EDT - 6 weeks ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

May 8, 2025, 8:05 AM EDT - 6 weeks ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

May 6, 2025, 8:05 AM EDT - 7 weeks ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

May 5, 2025, 8:00 AM EDT - 7 weeks ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Apr 21, 2025, 8:05 AM EDT - 2 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Mar 24, 2025, 8:00 AM EDT - 3 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:32 PM EST - 4 months ago

Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Feb 27, 2025, 8:05 AM EST - 4 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

Feb 26, 2025, 8:05 AM EST - 4 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Feb 20, 2025, 8:30 AM EST - 4 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

Feb 19, 2025, 8:05 AM EST - 4 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

IMUNON Appoints Douglas V. Faller, M.D.

Feb 10, 2025, 8:05 AM EST - 4 months ago

IMUNON Appoints Douglas V. Faller, M.D.

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Dec 19, 2024, 8:05 AM EST - 6 months ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

Dec 10, 2024, 8:05 AM EST - 7 months ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Nov 25, 2024, 8:05 AM EST - 7 months ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 5:11 PM EST - 8 months ago

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Nov 7, 2024, 10:00 AM EST - 8 months ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 7, 2024, 8:05 AM EST - 8 months ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Oct 31, 2024, 8:30 AM EDT - 8 months ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Oct 30, 2024, 9:05 AM EDT - 8 months ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 7, 2024, 8:05 AM EDT - 9 months ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Sep 9, 2024, 4:06 PM EDT - 10 months ago

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMUNON to Host R&D Day on September 18th

Aug 28, 2024, 8:30 AM EDT - 10 months ago

IMUNON to Host R&D Day on September 18th

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 2:55 PM EDT - 11 months ago

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 14, 2024, 8:00 AM EDT - 11 months ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Aug 7, 2024, 5:04 PM EDT - 11 months ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Jul 30, 2024, 1:07 PM EDT - 11 months ago

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Jul 30, 2024, 9:42 AM EDT - 11 months ago

Imunon's stock rockets after ovarian cancer treatment's positive trial results

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Jul 30, 2024, 8:00 AM EDT - 11 months ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Jul 29, 2024, 4:05 PM EDT - 11 months ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Jun 24, 2024, 8:30 AM EDT - 1 year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Jun 5, 2024, 8:30 AM EDT - 1 year ago

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

May 15, 2024, 8:30 AM EDT - 1 year ago

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

May 13, 2024, 6:05 PM EDT - 1 year ago

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

May 13, 2024, 9:00 AM EDT - 1 year ago

IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

May 8, 2024, 8:00 AM EDT - 1 year ago

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

May 6, 2024, 11:00 AM EDT - 1 year ago

IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024

IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101

Apr 18, 2024, 8:30 AM EDT - 1 year ago

IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101

IMUNON Reports Compliance with Nasdaq Listing Requirements

Apr 11, 2024, 8:00 AM EDT - 1 year ago

IMUNON Reports Compliance with Nasdaq Listing Requirements

NFD2
NFD2 Jun. 25 at 4:57 PM
$IMNN Imunon on #LinkedIn. Be sure to give them a follow!
0 · Reply
Yvon2025
Yvon2025 Jun. 25 at 4:35 PM
$IMNN By letting the stock price goes down that dip, the executives are sending a clear message: R/S is coming soon. Very painful they are planning to do this.
0 · Reply
RandomInvestor777
RandomInvestor777 Jun. 25 at 4:30 PM
$IMNN got some out of my fund to buy, however i will slowly buy as it goes down. This company is either getting a buyout or a partnership soon Imo. Their medicine is legit.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 Jun. 25 at 4:03 PM
$IMNN couldn’t buy today. Waiting for some money to clear. Should be good tomorrow for more shares.
0 · Reply
Cello69
Cello69 Jun. 25 at 3:40 PM
$IMNN Added .86
0 · Reply
Investnow54
Investnow54 Jun. 25 at 3:36 PM
$IMNN i would not care either if i knew i was going to be bought out. Its been explained the medicine works prolongs life where no one else can. I do not think phase 3 will just fall apart. This is robbery if your shares and lack of patience at play.
1 · Reply
ZacksSCR
ZacksSCR Jun. 25 at 3:07 PM
Replay available now: @OTCMarkets Virtual Investor Presentation with Stacy Lindborg, President, CEO, & Board Director of Imunon $IMNN, and David Bautz, PhD, SCR Senior Analyst https://buff.ly/IYhksSk #Biotech #DNAImmunotherapy #ImmunoOncology
0 · Reply
Goldpay55
Goldpay55 Jun. 25 at 2:58 PM
$IMNN at this pace we should be below .50 next week. Very disappointing to say the least
0 · Reply
I_AM_GROOT
I_AM_GROOT Jun. 25 at 2:49 PM
$IMNN shorty getting in before the 100K dump later today at the close like yesterday. They aren't dumb when it's telegraphed.
0 · Reply
OilBoomer
OilBoomer Jun. 25 at 1:49 PM
$IMNN Thought about selling this for a 30% loss but I'm just gonna hold and see if it doubles or goes to 0, not worth looking at each and every day.
0 · Reply
I_AM_GROOT
I_AM_GROOT Jun. 25 at 1:46 PM
$IMNN more like today then 40's by Fri
0 · Reply
StayPumpMarshmallow
StayPumpMarshmallow Jun. 25 at 1:45 PM
$IMNN Should be in the .70s by eod Friday. Buying time.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 Jun. 25 at 1:35 PM
$IMNN most people don’t realize how nasty ovarian cancer is. Breast cancer can be bad but nothing like ovarian. Any rich guy married to a woman with ovarian or son of a woman with ovarian will find this company and buy it out. No brainer IMO.
0 · Reply
NFD2
NFD2 Jun. 25 at 1:09 PM
$IMNN This is a stock that when it hits, there will be no stopping it. Timing…well, who knows! But near future. With their research and continued testing, this is a no brainer. Are you going to make a ton of money today or tomorrow? Maybe, who knows. Are you going to make a ton when this takes off? Absolutely. Patience.
0 · Reply
Shrekislove69
Shrekislove69 Jun. 25 at 1:09 PM
$IMNN I do like how there’s been no pr since the conference! Makes me think something big is coming up
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 Jun. 24 at 9:48 PM
$IMNN this is not a revenue generating enterprise. It’s an expert level science project with the executive team all coming from big pharma trying to score a big pay day. They will do whatever it takes to get a buyout. Just have to wait.
2 · Reply
Mad_Macks
Mad_Macks Jun. 24 at 9:27 PM
$IMNN long and strong on P2 results🤘🏻
0 · Reply
Mad_Macks
Mad_Macks Jun. 24 at 9:23 PM
$IMNN the warrant holders need a shareholder vote to exercise. Just chill till they do. Warrant holders are taught to hedge their position until they exercise so just get comfy with the pullback until that’s approved. I think the NASDAQ listinghearing and is all contingent on what happens at the board meeting. It’s unfortunate, but I think they receive some bad financial council as they were navigating the delisting challenge. Good riddance imo.
0 · Reply
ConcernedCitizen23
ConcernedCitizen23 Jun. 24 at 8:46 PM
$IMNN gonna buy more tomorrow
1 · Reply
Tomyw
Tomyw Jun. 24 at 8:29 PM
$IMNN disappointed AOC care should go private
1 · Reply
MrEd916
MrEd916 Jun. 24 at 8:26 PM
$IMNN I think this was one of those days where someone hoped to see a big bounce so they could sell at the top. Then realized it wasn't gonna happen today and so they bailed.
1 · Reply
Yassin_tet
Yassin_tet Jun. 24 at 8:08 PM
$IMNN straight to the gutter
0 · Reply